
NSAIDs使用合并Hp感染致研究学习ppt课件.pptx
74页NSAIDs使用合并Hp感染致消化道损伤的防治PPI治疗NSAID相关胃溃疡的临床优势 Kay Brune and Burkhard Hinz. The Discovery and Development of Antiinflammatory Drugs. ARTHRITIS & RHEUMATISM 2004; 50: 23912399阿斯匹林、非那西汀、咖啡因1936年“何济公,何济公,止痛唔使五分钟何济公,何济公,止痛唔使五分钟”Discovery of cortisone. In the late 1940s, E. Kendall and T. Reichstein discovered cortisone, which was first administered by P. Hench to a patient with rheumatoid arthritis. Raoul Dufy, a French painter with rheumatoid arthritis, came to the US for cortisone treatment in 1950. Pleased by the effect of the drug, he painted “La Cortisone” in 1951 and continued to paint until his death in 1953 from an acute gastric hemorrhage.In 1938 Douthwaite and Lintott provided the first endoscopic evidence that aspirin caused gastric mucosal damage. Images show gastric antrum before (left) and after (right) administration of aspirinLancet 1938;ii:1222-5阿司匹林使用前阿司匹林使用前阿司匹林使用后阿司匹林使用后NSAID相关性胃肠损害NSAID的胃肠损害表现l消化不良l食管炎l食管狭窄l胃十二指肠糜烂,溃疡、出血、穿孔l小肠、大肠溃疡,出血,穿孔l结肠炎OutlineNSAIDs相关性胃溃疡发生机制、临床特征PPI治疗NSAIDs相关性胃溃疡NSAIDs相关性胃溃疡的预防-PPI的作用-PPI治疗胃溃疡-PPI在幽门螺杆菌(Hp)阳性NSAIDs相关性胃溃疡中的作用-PPI在NSAIDs相关性胃溃疡并出血中的价值-PPI vs 米索前列醇 vs H2RA vs 胃黏膜保护剂NSAIDs相关性胃溃疡发生机制、临床特征相关性胃溃疡发生机制、临床特征心内科、风湿免疫科病人:NSAIDs使用 3个月GUDU粘膜糜烂粘膜正常马师洋,博士论文,2009GUDUSales of non-steroidal anti-inflammatory drugs (NSAIDs) in daily defined doses (DDD)/1000 inhabitants/day and hospitalisation rate for peptic ulcer bleeding (hospitalisations for bleeding per 100 000 inhabitants) in Sweden in 20002008. (A and B) Represent men and women, respectively. NSAIDs in mem (Rmale=0.6571, Pmale=0.05Lu Y, Sverdn E, Ljung R, et al. BMJ Open 2013;3:e002056.NSAID使用 VS 胃肠出血Sales of proton pump inhibitors (PPIs) in daily defined doses (DDDs)/1000 inhabitants/day and 30-day death of peptic ulcer bleeding (number of deaths within 30 days/100 hospitalisations for bleeding) in Sweden 20002008. (A and B) Represent men and women, respectively.NSAIDs correlated with re-bleeding in women (Rmale=0.8754, Pmale=0.002 and Rfemale=0.7161, Pfemale=0.03, respectively), but not in men.Lu Y, Sverdn E, Ljung R, et al. BMJ Open 2013;3:e002056.NSAID使用 VS 胃肠再出血随年龄增加,NSAID相关并发症住院率显著增加 BMJ 2001; 323:1236-39 Rahme E, et al. Cost of prescribed NSAID-related gastrointestinal adverse events in elderly patients Br J Clin Pharmacol, 2001; 52, 185-192NSAID相关性GI事件耗费大量金钱为什么NSAID会导致胃粘膜损害:防御 VS 损伤胃粘膜损害胃粘膜损害-防御因子平衡防御因子平衡正正常常胃胃内内,粘粘膜膜损损伤伤经经常常发发生生,而而粘粘膜膜能能快快速速修修复复,形形成成动态平衡动态平衡胃粘膜损害胃粘膜损害-防御因子形成动态平衡防御因子形成动态平衡1.胃黏膜损伤与保护基础与临床,上海科学技术出版社:20042.Hotta.Trends in Glycoscience and Glycotechnology. 2000;12(63):59-683. Fiorucci S, et al. Digest Liver Dis, 2001; 33(suppl 2): S35-43防御因素防御因素损害因素损害因素胃粘膜防御机制:依解剖和功能分为五个层次胃粘膜防御机制:依解剖和功能分为五个层次pH=2.0pH=7.0H+HCO3-sIgA第第第第一一一一层层层层:胃胃胃胃酸酸酸酸、粘粘粘粘液液液液- -碳碳碳碳酸酸酸酸氢氢氢氢盐盐盐盐、免疫球蛋白等免疫球蛋白等免疫球蛋白等免疫球蛋白等第第第第二二二二层层层层:上上上上皮皮皮皮细细细细胞胞胞胞、细细细细胞胞胞胞间间间间连连连连接接接接、基底膜基底膜基底膜基底膜第第第第三三三三层层层层:粘粘粘粘膜膜膜膜微微微微循循循循环环环环、及及及及粘粘粘粘膜膜膜膜下下下下传入神经传入神经传入神经传入神经第第第第四四四四层层层层:粘粘粘粘膜膜膜膜免免免免疫疫疫疫细细细细胞胞胞胞,如如如如肥肥肥肥大大大大细胞、巨噬细胞等细胞、巨噬细胞等细胞、巨噬细胞等细胞、巨噬细胞等第五层:胃腺重建、生长因子第五层:胃腺重建、生长因子第五层:胃腺重建、生长因子第五层:胃腺重建、生长因子Wallace JL, Granger DN. FASEB,1996;10:731-4粘膜防御修复的核心环节:粘膜防御修复的核心环节:粘膜微循环粘膜微循环前列腺素(前列腺素(前列腺素(前列腺素(PGPG)与胃粘膜血流)与胃粘膜血流)与胃粘膜血流)与胃粘膜血流GASTROENTEROLOGY 2008;135:4160非离子化NSAID 离子化NSAID 细胞膜通透性 细胞内高浓度聚集 (不易跨膜转运)含羧基的酸性衍生物胃腔(酸性环境)NSAID细胞毒作用损伤胃粘膜屏障NSAID损害胃肠粘膜:局部作用损害胃肠粘膜:局部作用NSAID损害胃肠粘膜:系统作用Gastroenterology 2008;135: 41-60NSAIDs相关性胃溃疡临床特征相关性胃溃疡临床特征NSAID溃疡的临床特点-GUDU-多发-较大-无痛80%有严重NSAID相关GI并发症的病人以前都无GI症状Am J Med 1998-上消化道症状( 45%) 烧心、恶心、呕吐、消化不良、腹痛-粘膜病损(20 30%) 内镜或X线所见-症状性溃疡(2.5 4.5%)-严重GI并发症(1 1.5%/年) 溃疡出血、穿孔和梗阻Ann Intern Med 1995 PPI治疗NSAIDs相关性胃溃疡NSAID-induced GU治疗目的不同,对胃内最适pH值所需的维持时间也不同 -酸相关性消化不良:pH3,12h以上/天-消化性溃疡:pH3,18h以上/天-反流性食管炎:pH4,18h以上/天-根除幽门螺杆菌:pH5,18h以上/天-上消化道出血:pH6,20h以上/天1987Omeprazole1992Lansoprazole1994Pantoprazole1998Rabeprazole2002EsomeprazolePPI的发展与奥美拉唑相比,后续的PPI主要在以下两个方面寻求提高:Malcolm Robinson and John Horn, Drugs, 2003: 63(24): 2739-2754-抑酸的起效时间-减少人群间的差异PPI在PU治疗中作用-治疗2周、4周、8周后,DU愈合率可达75%、95%及100%-治疗4周及8周后,GU的愈合率分别为85%及98%-病人的症状在服药后迅速缓解Farthing MJG. Drug therapy for gastrointestinal and liver diseases. 2001幽门螺杆菌感染(Helicobacter pylori, Hp)Hp+NSAID对胃肠黏膜损害增加?降低?Hp感染增加溃疡危险性% 溃疡病人NSAID+Hp+NSAID+Hp-NSAID-Hp+NSAID-Hp-OR= 2.4O.R. 2.1Huang et al. Lancet 2001Meta-analysis of 12 studies consistingof 1901 patientsNSAIDsHp局部效应+全身效应粘液碳酸氢盐血流细胞恢复中性粒细胞细胞毒素,LPS,HSP,酶,et al免疫级联反应中性粒细胞淋巴细胞细胞因子,等等H+H+H+胃蛋白酶胃蛋白酶NSAIDs与Hp的协同作用机制中华内科杂志 2012; 51(10): 832-836哪些人需根除Hp:适应证幽门螺杆菌阳性疾病消化性溃疡(不论是否活动和有无并发症史)胃黏膜相关淋巴组织(MALT)淋巴瘤慢性胃炎伴消化不良症状慢性胃炎伴胃黏膜萎缩或糜烂早期胃肿瘤已行内镜下切除或手术胃次全切除长期服用质子泵抑制剂胃癌家族史计划长期服用NSAID(包括低剂量阿斯匹林)不明原因的缺铁性贫血特发性血小板减少性紫癜(ITP)其他幽门螺杆菌相关性疾病(如淋巴细胞性胃炎、增生性胃息肉、Mntrier病)个人要求治疗阿莫西林+克拉霉素;阿莫西林+左氧氟沙星阿莫西林+呋喃唑酮;四环素+甲硝唑或呋喃唑酮;PPI+铋剂铋剂+两种两种抗生素抗生素推荐什么方案?推荐四联方案:标准剂量PPI标准剂量铋剂(均为2次/d,餐前半小时)2种抗菌药物(餐后即服);疗程10d或14d中华内科杂志 2012; 51(10): 832-836中国方案埃索美拉唑三联方案的Hp根除率Tulassay Z, et al.Eur J Gastroenterol Hepatol. 2001;13(12):1457-65.Veldhuyzen ZS, et al. Aliment Pharmacol Ther. 2000;14(12):1605-11.Hp根除率(%)EAC:埃索美拉唑20mg、阿莫西林1g、克拉霉素500mg, bidOAC:奥美拉唑20mg、阿莫西林1g、克拉霉素500mg, bid14%58%- 根除DU愈合方面优于非根除组(RR=0.66)- GU愈合方面两组无差异-。












